JP2007501862A5 - - Google Patents

Download PDF

Info

Publication number
JP2007501862A5
JP2007501862A5 JP2006533468A JP2006533468A JP2007501862A5 JP 2007501862 A5 JP2007501862 A5 JP 2007501862A5 JP 2006533468 A JP2006533468 A JP 2006533468A JP 2006533468 A JP2006533468 A JP 2006533468A JP 2007501862 A5 JP2007501862 A5 JP 2007501862A5
Authority
JP
Japan
Prior art keywords
ylene
phen
alkyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006533468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501862A (ja
JP4616264B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/016781 external-priority patent/WO2004106333A1/en
Publication of JP2007501862A publication Critical patent/JP2007501862A/ja
Publication of JP2007501862A5 publication Critical patent/JP2007501862A5/ja
Application granted granted Critical
Publication of JP4616264B2 publication Critical patent/JP4616264B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006533468A 2003-05-28 2004-05-27 ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物 Expired - Fee Related JP4616264B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47376103P 2003-05-28 2003-05-28
PCT/US2004/016781 WO2004106333A1 (en) 2003-05-28 2004-05-27 Azabicycloalkane compounds as muscarinic receptor antagonists

Publications (3)

Publication Number Publication Date
JP2007501862A JP2007501862A (ja) 2007-02-01
JP2007501862A5 true JP2007501862A5 (2) 2007-05-31
JP4616264B2 JP4616264B2 (ja) 2011-01-19

Family

ID=33490645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533468A Expired - Fee Related JP4616264B2 (ja) 2003-05-28 2004-05-27 ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物

Country Status (7)

Country Link
US (3) US7358244B2 (2)
EP (1) EP1626970B1 (2)
JP (1) JP4616264B2 (2)
AT (1) ATE435862T1 (2)
DE (1) DE602004021921D1 (2)
ES (1) ES2329133T3 (2)
WO (1) WO2004106333A1 (2)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE602004021921D1 (de) * 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
US20080051582A1 (en) * 2006-07-10 2008-02-28 Sicor Inc. Process for the preparation of tiotropium bromide
WO2008041095A1 (en) * 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
WO2008104955A1 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
SG2012079653A (en) 2007-10-25 2014-05-29 Exelixis Inc Tropane compounds
HRP20141004T1 (hr) * 2008-01-10 2015-02-13 Generics Novi postupak pripreme estera skopina
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
PL2242759T3 (pl) * 2008-02-06 2013-06-28 Astrazeneca Ab Związki
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
MX2011007036A (es) 2008-12-30 2011-07-20 Pulmagen Therapeutics Inflammation Ltd Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
MX2011011446A (es) 2009-04-30 2011-11-18 Teijin Pharma Ltd Compuestos de sal de amonio cuaternario.
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
NZ597920A (en) 2009-08-07 2014-05-30 Generics Uk Ltd Anhydrate of tiotropium bromide
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
BR112013030302B1 (pt) 2011-06-10 2021-08-24 Chiesi Farmaceutici S.P.A. Composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104034822B (zh) * 2014-06-27 2016-04-20 宁波检验检疫科学技术研究院 一种测定食品接触用纸制品中乙二醛含量的方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) * 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
WO2017001907A1 (en) * 2015-06-29 2017-01-05 Teva Pharmaceuticals International Gmbh Biocatalytic processes for the preparation of vilanterol
CA2997545C (en) * 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof
CN107305199B (zh) * 2016-04-19 2021-04-13 重庆华邦制药有限公司 分离测定盐酸氮卓斯汀丙酸氟替卡松复方鼻喷雾剂中两组分及有关物质的方法
RU2722720C1 (ru) * 2016-12-14 2020-06-03 Бейджинг Шоубай Фармасьютикэл Ко., Лтд. Класс бифункциональных соединений со структурой соли четвертичного аммония
CN114057684B (zh) * 2020-08-08 2023-09-26 鲁南制药集团股份有限公司 一种噻托溴铵中间体二(2-二噻吩基)羟乙酸甲酯的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505337A (en) * 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
WO1993001165A2 (en) * 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, compositions containing them and their use in therapy
US5770738A (en) * 1992-03-05 1998-06-23 Boehringer Ingelheim Kg Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
EP0916074B1 (en) * 1997-05-29 2003-07-30 AMS International AG Magnetic rotation sensor
WO1999064043A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Muscarinic receptor antagonists
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US20020111363A1 (en) * 2000-10-31 2002-08-15 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
DE60121813T2 (de) 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
DE10216339A1 (de) 2002-04-13 2003-10-23 Boehringer Ingelheim Pharma Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
DE10255040A1 (de) 2002-11-26 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbaminsäureester mit anticholinerger Wirksamkeit
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
DE602004021921D1 (de) * 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten

Similar Documents

Publication Publication Date Title
JP2007501862A5 (2)
JP2006522134A5 (2)
JP2007514662A5 (2)
JP2008510014A5 (2)
JP2008510015A5 (2)
RU2005128557A (ru) Производные бифенила
ES2576497T3 (es) Compuesto de piperidina novedoso o sal del mismo
JP5932848B2 (ja) アモルファス（５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸
JP2017515856A5 (2)
CA3030821C (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF A SYMPTOM ASSOCIATED WITH GOUT OR HYPEROURICEMIA
HRP20191433T1 (hr) Inhibitori arginaze i metode primjene
JP2006509749A5 (2)
JP2008513498A5 (2)
JP2007520520A5 (2)
BR112021008232A2 (pt) conjugados citostáticos inovadores com ligantes de integrina
JP2023543059A5 (2)
CN105130959B (zh) 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
JP2013540114A5 (2)
JP2021522201A (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
RU2009104764A (ru) Производные пурина, как антангонисты a2a
JP2017537977A (ja) チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
JP2013542267A5 (2)
CA3222952A1 (en) Dendrimer conjugates and methods of use thereof
JP5634862B2 (ja) 低粘度アントラサイクリン製剤
JP2024177285A (ja) リン酸化タウタンパク質への結合を介した神経障害を検出する方法